Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836
Excellent safety continues to be observed in ongoing Phase 2a dose optimization study (OVX836-003) Phase 2a dose optimization study extended to elderly population cohort (OVX836-003) Additional Phase 2a trial combining OVX836 with conventional quadrivalent influenza vaccine (QIV) initiated with first participants enrolled in Australia (OVX836-004) LYON, France–(BUSINESS WIRE)–Osivax, a biopharmaceutical company developing vaccines to provide … [Read more…]